Budget 2026: The Roadmap for ‘Heal in India’ & Science R&D

A developed nation cannot be built on borrowed technology or a fragile healthcare system. In Union Budget 2026-27, the government has acknowledged this reality, shifting the focus from “treating illness” to “fostering innovation.”

While the headline allocation for healthcare has seen a steady rise, the real story lies in the Science & Technology allocation—specifically the operationalization of the ‘Anusandhan’ National Research Fund.

Here is how the 2026 budget aims to transform India into a global pharmacy and research hub.

1. The “Anusandhan” Era Begins

(Target Keyword: Anusandhan National Research Fund)

The highlight of the Science budget is the full-scale launch of the “Anusandhan” corpus.

• The Corpus: A massive ₹1 Lakh Crore pool (interest-free loans) is now live to encourage the private sector to scale up research and innovation.
• The Goal: To move India from “adopting technology” to “generating technology” in sunrise sectors like Deep Tech, Bio-Pharma, and Defense.
• Impact: This is a game-changer for R&D-heavy companies that previously struggled with the high cost of capital.

2. “Heal in India”: Infrastructure & Education

The budget continues the mission to make India a medical tourism destination (“Heal in India”) while strengthening domestic care.

• New Nursing Colleges: Co-location of 157 new nursing colleges with existing medical colleges is being fast-tracked to fix the global shortage of nurses.
• Sickle Cell Elimination: The mission to eliminate Sickle Cell Anemia by 2047 receives a funding boost for screening 7 crore people in tribal areas.
• Cervical Cancer: Encouragement of vaccination for girls aged 9-14 remains a key preventive health priority.

3. Pharma & MedTech: Ending Import Dependence

(Target Keyword: Medical device industry budget)

India is known as the “Pharmacy of the World” for generics, but we still import high-end medical devices (like MRI machines and stents).

• MedTech Parks: The budget proposes new incentives for manufacturing high-end medical devices domestically.
• Pharma PLI: Continued support for the Production Linked Incentive (PLI) scheme to boost the manufacturing of Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs), reducing reliance on Chinese imports.

4. Visualizing the R&D Shift

To understand why the government is obsessed with R&D, look at this comparison of Gross Expenditure on R&D (GERD) as a percentage of GDP. India aims to cross the 1% mark rapidly.

Image Metadata:

• Alt Text: A bar chart comparing R&D spending (GERD) of Developed Nations (2-3%) vs India’s current (<0.7%) and India’s 2030 Target (>1%).
• Caption: The Gap: India’s “Anusandhan” push aims to bridge the R&D deficit against global peers.peers.
  
  5. Investment Outlook: Who Wins?
  If you are an investor, here is how to read these announcements:

5. Investment Outlook: Who Wins?

If you are an investor, here is how to read these announcements:

Frequently Asked Questions (FAQs)

Amit Sharma

Amit Sharma is the Founder and Lead Editor of Invest With Bull.
A data-driven investor and financial content strategist, Amit has spent over a decade navigating the Indian stock market. Frustrated by generic financial advice, he launched Invest With Bull to provide unbiased, research-backed insights for the modern Indian investor.
Unlike theoretical pundits, Amit writes from experience. He specializes in:
Core Areas of Expertise:

Credit & Debt Strategy: Expert in optimizing credit card reward structures and managing unsecured loans to maximize lifestyle benefits while minimizing interest.

Mutual Fund Analysis: specialized in decoding expense ratios and rolling returns to identify consistent wealth creators.

Personal Finance: Proven strategies for tax planning and smart spending for the Indian middle class.

His work focuses on “Systematic Wealth Creation”—moving beyond get-rich-quick schemes to build a resilient, compounding portfolio.